TA
Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
$78.09 -1.01% (-$0.80)
1M +7.41%
Market Cap $3.40B
P/E Ratio -
Div. Yield -
ROE 13.53%
Bulios Fair Price
$109.17
39.8% upside
Current Price
$78.09
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TARS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
6 /100
Expensive P/B 9.81x
P/FCF 55.25x
P/S 5.61x
Growth
100 /100
Growing Book val. growth 21.20%
Rev. growth 159.54%
FCF growth N/A
Profitability
40 /100
Moderate Net margin 7.67%
Op. margin 8.00%
FCF margin 10.15%
Quality
12 /100
Poor ROE 13.53%
ROA 7.60%
Asset turnover 0.99x
Debt
69 /100
Low Current ratio 3.20x
Int. coverage -4.36x
Debt/Equity 0.26x
Stability
25 /100
Unstable Rev. volatility 522.43%
EPS volatility 72.09%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TARS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Bobak R. Azamian
Employees
370
Headquarters
Irvine
Upcoming events
03 NOV
Earnings
Upcoming earnings report